Bristol-Myers Squibb’s $74 billion mega-merger with Celgene seems to have been vindicated after a set of glowing full-year results from the previously struggling pharma.
Almost half of cancer patients reported that their medical care team did not discuss clinical trials with them, and often discouraged participation when the subject was discussed, according
